Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1977 1
1988 1
1992 1
1993 2
1994 1
1995 1
1996 3
1997 1
1998 5
1999 2
2000 4
2001 1
2002 4
2003 3
2004 4
2005 6
2006 13
2007 11
2008 20
2009 21
2010 22
2011 18
2012 25
2013 42
2014 78
2015 84
2016 117
2017 115
2018 134
2019 165
2020 213
2021 225
2022 248
2023 230
2024 66

Text availability

Article attribute

Article type

Publication date

Search Results

1,664 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
Fu Z, Li S, Han S, Shi C, Zhang Y. Fu Z, et al. Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038/s41392-022-00947-7. Signal Transduct Target Ther. 2022. PMID: 35318309 Free PMC article. Review.
Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. ...Since the first ADC, Mylotarg() (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug
Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug vi …
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Levey AS, et al. Am J Kidney Dis. 2020 Jan;75(1):84-104. doi: 10.1053/j.ajkd.2019.06.009. Epub 2019 Aug 28. Am J Kidney Dis. 2020. PMID: 31473020
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression …
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% t …
Antibodies to watch in 2022.
Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Kaplon H, et al. MAbs. 2022 Jan-Dec;14(1):2014296. doi: 10.1080/19420862.2021.2014296. MAbs. 2022. PMID: 35030985 Free PMC article. Review.
As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the United States or European Union in 2021 (evinacumab, dostarlimab loncastuximab tesirine, amivantamab, aducanumab, tralokinumab, anifrolumab, bimekizumab, tisotumab v …
As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the United States or European …
Predictive biomarkers of colon cancer immunotherapy: Present and future.
Hou W, Yi C, Zhu H. Hou W, et al. Front Immunol. 2022 Nov 22;13:1032314. doi: 10.3389/fimmu.2022.1032314. eCollection 2022. Front Immunol. 2022. PMID: 36483562 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instability (MSI-H). In 2020, the US Food and Drug Administration (FDA)-approved ICI pembrolizumab as the first-line treatmen …
Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instab …
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Zhong L, et al. Signal Transduct Target Ther. 2021 May 31;6(1):201. doi: 10.1038/s41392-021-00572-w. Signal Transduct Target Ther. 2021. PMID: 34054126 Free PMC article. Review.
Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, an increasing number of small-molecule targeted drugs have been developed for the treatment of malignancies. By December …
Since the first tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration
Amivantamab: First Approval.
Syed YY. Syed YY. Drugs. 2021 Jul;81(11):1349-1353. doi: 10.1007/s40265-021-01561-7. Drugs. 2021. PMID: 34292533 Review.
Amivantamab is in preregistration for NSCLC in the EU, Australia, Japan, Canada, Switzerland and China. This article summarizes the milestones in the development of amivantamab leading to this first approval for NSCLC....
Amivantamab is in preregistration for NSCLC in the EU, Australia, Japan, Canada, Switzerland and China. This article summarizes the m …
Targeting tumor microenvironment in ovarian cancer: Premise and promise.
Jiang Y, Wang C, Zhou S. Jiang Y, et al. Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188361. doi: 10.1016/j.bbcan.2020.188361. Epub 2020 Mar 29. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32234508 Review.
The majority of ovarian cancer patients suffer from relapse after standard of care therapies and the clinical benefits from cancer therapies are not satisfactory owing to drug resistance. Certain novel drugs targeting the components of tumor microenvironment (TME) have bee …
The majority of ovarian cancer patients suffer from relapse after standard of care therapies and the clinical benefits from cancer therapies …
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives.
Liu P, Chen G, Zhang J. Liu P, et al. Molecules. 2022 Feb 17;27(4):1372. doi: 10.3390/molecules27041372. Molecules. 2022. PMID: 35209162 Free PMC article. Review.
Liposomes have been considered promising and versatile drug vesicles. Compared with traditional drug delivery systems, liposomes exhibit better properties, including site-targeting, sustained or controlled release, protection of drugs from degradation and clearance, …
Liposomes have been considered promising and versatile drug vesicles. Compared with traditional drug delivery systems, liposom …
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, Tang X, Yaron TM, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen DT, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Han Y, et al. Nature. 2021 Jan;589(7841):270-275. doi: 10.1038/s41586-020-2901-9. Epub 2020 Oct 28. Nature. 2021. PMID: 33116299 Free PMC article.
Using hPSC-LOs, we performed a high-throughput screen of drugs approved by the FDA (US Food and Drug Administration) and identified entry inhibitors of SARS-CoV-2, including imatinib, mycophenolic acid and quinacrine dihydrochloride. ...Together, these data d …
Using hPSC-LOs, we performed a high-throughput screen of drugs approved by the FDA (US Food and Drug Administration) an …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.
Wu Q, Qian W, Sun X, Jiang S. Wu Q, et al. J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. ...Our analysis of existing challenges and potential opportunities in drug development may advance soli …
The United States Food and Drug Administration (US FDA) has always been a forerunner in drug
1,664 results